Sökning: "lenalidomide"

Visar resultat 1 - 5 av 10 avhandlingar innehållade ordet lenalidomide.

  1. 1. Mantle cell lymphoma strategies in primary treatment

    Författare :Alexandra Albertsson Lindblad; Tumörmikromiljö; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; mantle cell lymphoma; registry data; Clinical Trial; Phase I; Clinical Trial; Phase II; rituximab; bendamustine; lenalidomid; ibrutinib; ADCC; in vitro model; TP53 mutations; watchful waiting; mantle cell lymphoma; real-world data; lenalidomide; rituximab; bendamustin; ibrutinib; ADCC; TP53 mutation; CDKN2A; NGS; MIPI; Watchful waiting;

    Sammanfattning : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. LÄS MER

  3. 2. Studies of anemia in the myelodysplastic syndromes

    Författare :Martin Jädersten; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Myelodysplasia; growth factors; Cox regression; delayed entry; left truncation; mortality; international prognostic scoring system; IPSS; who-classification based prognostic scoring system; WPSS; thalidomide analogue; IMiD; hematopoietic stem cell; adhesion; stroma; matrix; osteonectin; matricellular protein; NPM1; immunohistochemistry.;

    Sammanfattning : Background: The myelodysplastic syndromes (MDS) constitute a heterogeneous group of malignant bone marrow disorders, characterized by chronic anemia and increased risk of transformation to acute myeloid leukemia (AML). The first line therapy of anemia in MDS is erythropoietin (EPO) with or without granulocyte colony-stimulating factor (G-CSF). LÄS MER

  4. 3. The mutational landscape and microenvironment in myelodysplastic syndromes with deletion of chromosome 5q

    Författare :Christian Scharenberg; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Myelodysplastic Syndromes (MDS) with deletion of chromosome 5q (del(5q) are malignant bone marrow disorders characterized by macrocytic anemia, chronic transfusion dependency and an increased risk of progression to acute myeloid leukemia. A high proportion of patients with lower-risk del(5q) myelodysplastic syndromes will respond to lenalidomide treatment, but more than 40% of patients have progressed to acute leukemia five years after starting treatment. LÄS MER

  5. 4. Follicular lymphoma : clinical and biological factors associated with response to therapy and overall prognosis

    Författare :Sandra Johanna Young Lockmer; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Follicular lymphoma (FL) is a heterogeneous group of malignancies within the adaptive immune system. The clinical course is highly variable. Treatment includes different chemotherapy regimens as well as the anti-CD20 monoclonal antibody rituximab which has significantly improved the prognosis for patients with all types of B cell lymphomas. LÄS MER

  7. 5. TP53 mutations in myelodysplastic syndromes with deletion of 5q

    Författare :Leonie Saft; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : The myelodysplastic syndromes (MDS) constitute a heterogeneous group of malignant bone marrow disorders characterized by peripheral cytopenia(s) and increased risk of progression to acute myeloid leukemia (AML). International Prognostic Scoring system (IPSS) Low- or Intermediate (INT)-1 risk MDS with a deletion of 5q (del5q) were considered to have an indolent course and a low risk for progression to AML as compared to other MDS subtypes. LÄS MER